Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells

Martina Lukasova,1,2 Camille Malaval,1 Andreas Gille,2 Jukka Kero,2 and Stefan Offermanns1,2,3

1Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
2Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany. 3Medical Faculty, Goethe University Frankfurt, Frankfurt, Germany.

Nicotinic acid (niacin) is a drug used to reduce the progression of atherosclerosis. Its antiatherosclerotic activity is believed to result from lipid-modifying effects, including its ability to decrease LDL cholesterol and increase HDL cholesterol levels in plasma. Here, we report that in a mouse model of atherosclerosis, we found that nicotinic acid inhibited disease progression under conditions that left total cholesterol and HDL cholesterol plasma levels unaffected. The antiatherosclerotic effect was not seen in mice lacking the receptor for nicotinic acid GPR109A. Surprisingly, transplantation of bone marrow from GPR109A-deficient mice into atherosclerosis-prone animals also abrogated the beneficial effect of nicotinic acid. We detected expression of GPR109A in macrophages in atherosclerotic plaques. In macrophages from WT mice, but not from GPR109A-deficient animals, nicotinic acid induced expression of the cholesterol transporter ABCG1 and promoted cholesterol efflux. Furthermore, activation of GPR109A by nicotinic acid inhibited MCP-1–induced recruitment of macrophages into the peritoneal cavity and impaired macrophage recruitment to atherosclerotic plaques. In contrast with current models, our data show that nicotinic acid can reduce the progression of atherosclerosis independently of its lipid-modifying effects through the activation of GPR109A on immune cells. We conclude therefore that GPR109A mediates antiinflammatory effects, which may be useful for treating atherosclerosis and other diseases.

Introduction

Nicotinic acid has been used for decades as an antidyshlipidemic drug to prevent and treat atherosclerosis (1, 2). Shortly after the discovery of the cholesterol-lowering effect of nicotinic acid by Altschul, its antiatherosclerotic effect was first observed in rabbits (3). Later, a reduction in atherosclerotic lesion size was also seen in other experimental animal models in response to nicotinic acid and its derivatives (4–7). The first evidence for antiatherosclerotic effects of nicotinic acid in humans came from angiographic studies showing regression of atherosclerosis in coronary and peripheral arteries under nicotinic acid treatment (8, 9). Furthermore, the Coronary Drug Project demonstrated a reduction in cardiovascular events and mortality in patients treated with nicotinic acid (10, 11). More recently, studies in which nicotinic acid was added to statin therapy have yielded promising data indicating that nicotinic acid enhances the effect of statins to reduce the risk of cardiovascular events and to slow the progression of atherosclerosis in patients with low levels of HDL cholesterol and established atherosclerotic cardiovascular disease (12–15).

Several mechanisms have been proposed to account for the antiatherosclerotic effects of nicotinic acid (16–18). The prevailing view holds the antidyshlipidemic effects of nicotinic acid primarily accountable for its beneficial clinical effects. At pharmacological doses, nicotinic acid reduces LDL cholesterol, triglyceride, and lipoprotein(a) plasma levels while increasing levels of HDL cholesterol (1). One mechanism responsible for the lipid-modifying effects of nicotinic acid is the activation of the G-protein–coupled receptor GPR109A expressed on adipocytes (19–21). Activation of GPR109A on fat cells has an antilipolytic effect leading to a decreased release of free fatty acids from adipocytes. The reduced supply of free fatty acids to the liver then leads to reduced triglyceride synthesis, VLDL production, and LDL cholesterol levels (22). It has been proposed that the decrease in triglyceride content of ApoB-containing lipoproteins decreases the exchange of triglyceride for cholesteryl esters from HDL particles mediated by the cholesterol ester transfer protein (CETP), resulting in increased HDL cholesterol levels (23, 24). In fact, HDL cholesterol elevation in response to nicotinic acid in mice has been shown to depend on the presence of CETP (25, 26). However, the partial GPR109A agonist MK-0354 reduced plasma free fatty acid levels but failed to raise HDL cholesterol levels in humans (27, 28). While the lack of changes in HDL cholesterol levels could be due to the reduced efficacy of MK-0354 compared with nicotinic acid, it may also argue against a link between the antilipolytic effects of nicotinic acid and an increase in HDL cholesterol plasma levels. Another mechanism that might contribute to the increase in HDL cholesterol levels in response to nicotinic acid is a lowering of the hepatic uptake of ApoA1 observed in vitro and in vivo in mice (26, 29) or an increased production of ApoA1 as described in dyslipidemic humans (30). In addition, nicotinic acid at relatively high concentrations has been shown in vitro to inhibit diacylglycerol acyltransferase 2 (31); however, it remains unclear whether this effect is of significance under in vivo conditions.

Besides its lipid-modifying effects, nicotinic acid has various other activities that could be involved in its beneficial clinical effects. In endothelial cells, nicotinic acid has antioxidative and antiinflammatory effects and inhibits cytokine-induced expression of adhesion molecules and chemokines (32–34). These effects are unlikely to be directly mediated by the nicotinic acid receptor, as endothelial cells do not express GPR109A. GPR109A is

Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest doi:10.1172/JCI41651.
not only expressed in adipocytes but also in various immune cells including macrophages, neutrophils, and epidermal Langerhans cells, but not in lymphocytes (35–38). In leukocytes, nicotinic acid induces cellular effects, such as an increase in the intracellular Ca$^{2+}$ concentration or an increased formation of prostanoids (39–43).

In monocyte/macrophage cell lines, nicotinic acid stimulates PPAR$\gamma$ expression and enhances transcription of the oxidized LDL (oxLDL) scavenger receptor CD36 and of the cellular cholesterol efflux transporter ABCA1 (44, 45). Whether direct effects of nicotinic acid on inflammatory cells contribute to the antiatherosclerotic effects of nicotinic acid remains, however, unknown.

The present study was undertaken in order to elucidate the mechanisms underlying the antiatherosclerotic effects of nicotinic acid. Using mice lacking the nicotinic acid receptor GPR109A and generating bone marrow chimeras, we show that nicotinic acid reduces the progression of atherosclerosis by direct GPR109A-mediated effects on bone marrow–derived cells. These data indicate that in addition to the antihyperlipidemic effects of nicotinic acid, a direct antiinflammatory effect of nicotinic acid, which is mediated through GPR109A on immune cells, underlies the beneficial effects of this antiatherosclerotic drug.

**Results**

*Nicotinic acid inhibits the progression of atherosclerosis through its receptor GPR109A.* In order to study the antiatherosclerotic effects of nicotinic acid in a rodent model accessible to genetic manipulations, we tested atherosclerosis-prone mice lacking the LDL receptor (LDL-R).

Treatment of male LDL-R-deficient mice kept on a high-fat diet (containing 1.5% cholesterol) with nicotinic acid reduced atherosclerotic lesion formation significantly (Figure 1). At a concentration of 0.3% nicotinic acid, a dose used before in mice (25, 26), the effect was maximal, and body weight as well as food intake were indistinguishable between treated and nontreated animals (data not shown). Nicotinic acid reduced atherosclerotic lesion size by about 25% in all regions of the aorta (Figure 1).

To test whether the effect of nicotinic acid involved the nicotinic acid receptor GPR109A, we performed parallel experiments in mice lacking both LDL-R ($Ldlr^{-/-}$) and GPR109A ($Gpr109a^{-/-}$). Whereas the extent of atherosclerotic lesion development was comparable in nontreated high-fat diet–fed $Ldlr^{-/-}$ and $Ldlr^{-/-};Gpr109a^{-/-}$ mice, the reduction in lesion size seen in $Ldlr^{-/-}$ animals treated with nicotinic acid was absent in mice also lacking GPR109A (Figure 1). Thus, the nicotinic acid receptor is critically involved in the antiatherosclerotic effect of nicotinic acid in LDL-R–deficient mice.

*Effect of nicotinic acid on plasma lipid levels in atherosclerosis-prone mice.* Nicotinic acid is believed to exert its antiatherosclerotic effects in humans through a decrease in total cholesterol and an increase in HDL cholesterol levels (1, 2). Since nicotinic acid failed to induce corresponding changes in plasma lipid levels in WT and ApoE-deficient mice as well as in various other animal species (46, 47), we evaluated the effect of nicotinic acid on...
the plasma concentrations of various lipid fractions in LDL-R-deficient mice kept on a high-fat diet for 2 or 10 weeks. Ldlr<sup>−/−</sup>; Gpr109<sup>−/−</sup> and Ldlr<sup>−/−</sup>;Gpr109a<sup>−/−</sup> animals had comparable levels of free fatty acids, triglycerides, total cholesterol, and HDL cholesterol. Of these parameters, only triglyceride levels showed a small reduction, by 11%–18.5%, in response to 2 weeks of nicotinic acid treatment (Figure 2, A and B). Size exclusion chromatography of serum from Ldlr<sup>−/−</sup>;Gpr109<sup>+</sup> and Ldlr<sup>−/−</sup>;Gpr109a<sup>−/−</sup> mice treated with normal chow or with a high-fat diet in the absence or presence of nicotinic acid showed no significant change in the distribution of cholesterol among VLDL, LDL, and HDL fractions (Figure 2, C–F). The phospholipid as well as the ApoAI and ApoAII content of HDL particles was not affected by nicotinic acid treatment (see Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI41651DS1).

Thus, GPR109A-dependent antiatherosclerotic effects of nicotinic acid were not accompanied by any changes in cholesterol or HDL cholesterol plasma concentrations.

GPR109A on bone marrow–derived cells mediates the antiatherosclerotic effects of nicotinic acid. Since GPR109A is not only expressed in adipocytes but also in various immune cells, we generated bone marrow chimeras by transplanting bone marrow from WT or GPR109A-deficient mice onto irradiated Ldlr<sup>−/−</sup> animals. 2 weeks after the transplantation, mice were put on a high-fat diet in the absence or presence of 0.3% nicotinic acid. Thereafter, free fatty acid, triglyceride (TG), and total cholesterol (TC) levels were determined (A and B). Shown are mean values of the indicated plasma lipid levels ± SEM; *P ≤ 0.05 compared with control value. (C–F) Serum samples from the indicated high-fat diet–fed animals treated without or with 0.3% nicotinic acid were pooled and analyzed for lipoprotein cholesterol profiles by FPLC as described in Methods. Shown are representative examples of at least 3 independently performed experiments.
Acid treatment resulted in a significant reduction of atherosclerotic lesion size in all areas of the aorta comparable to that of nontransplanted Ldlr<sup>−/−</sup> animals. Interestingly, this effect was not seen in mice that had received bone marrow from GPR109A-deficient animals (Figure 3). This indicates that the antiatherosclerotic effect of nicotinic acid in Ldlr<sup>−/−</sup> mice depends on GPR109A expressed on bone marrow–derived cells.

**GPR109A is expressed by macrophages in atherosclerotic plaques.** To further characterize cells that express GPR109A and may be involved in the antiatherosclerotic effects of nicotinic acid, we have generated a BAC-based transgenic mouse line expressing monomeric red fluorescent protein (mRFP) under the control of the mouse Gpr109a promoter (Gpr109a<sub>mRFP</sub>) (48). In 5 independent transgenic lines, we found expression of mRFP in adipocytes and in various tissues containing immune cells such as spleen or bone marrow (data not shown) reflecting the known expression pattern of GPR109A. To determine whether GPR109A-expressing cells are present in atherosclerotic lesions, we crossed the GPR109A reporter mouse line with LDL-R–deficient mice. Gpr109a<sub>mRFP</sub>;Ldlr<sup>−/−</sup> animals received a high-fat diet for 16 weeks, and thereafter whole aortae and aortic root sections of atherosclerotic lesions were analyzed by fluorescence microscopy (Figure 4). As shown in Figure 4A, strong RFP fluorescence was seen in whole-mount aortae from atherosclerotic mice carrying the GPR109A reporter transgene but not in whole-mount aortae from atherosclerotic Ldlr<sup>−/−</sup> mice without the Gpr109a<sub>mRFP</sub> transgene and from mice that were not atherosclerotic but carried the GPR109A reporter transgene (Ldlr<sup>−/−</sup>;Gpr109a<sub>mRFP</sub>). To further characterize the GPR109A-expressing cells in atherosclerotic plaques, we have generated a BAC-based transgenic mouse line expressing monomeric red fluorescent protein (mRFP) under the control of the mouse Gpr109a promoter (Gpr109a<sub>mRFP</sub>) (48). In 5 independent transgenic lines, we found expression of mRFP in adipocytes and in various tissues containing immune cells such as spleen or bone marrow (data not shown) reflecting the known expression pattern of GPR109A. To determine whether GPR109A-expressing cells are present in atherosclerotic lesions, we crossed the GPR109A reporter mouse line with LDL-R–deficient mice. Gpr109a<sub>mRFP</sub>;Ldlr<sup>−/−</sup> animals received a high-fat diet for 16 weeks, and thereafter whole aortae and aortic root sections of atherosclerotic lesions were analyzed by fluorescence microscopy (Figure 4). As shown in Figure 4A, strong RFP fluorescence was seen in whole-mount aortae from atherosclerotic mice carrying the GPR109A reporter transgene but not in whole-mount aortae from atherosclerotic Ldlr<sup>−/−</sup> mice without the Gpr109a<sub>mRFP</sub> transgene and from mice that were not atherosclerotic but carried the GPR109A reporter transgene (Ldlr<sup>−/−</sup>;Gpr109a<sub>mRFP</sub>).
In atherosclerotic lesions, we sectioned lesions and stained them with antibodies recognizing murine macrophages. Overlays of images indicate that most plaque areas that were RFP-positive corresponded to areas that were stained for macrophage antigens (Figure 4, B and C). These data show that GPR109A expression is strongly increased in atherosclerotic lesions of 

\[ \text{Ldlr}^{-/-}; \text{Gpr109a}^{mRFP} \] mice and that this appears to be due to the presence of GPR109A-expressing macrophages.

**Effects of nicotinic acid on macrophages.** We then tested whether nicotinic acid has effects on macrophages that might explain its inhibitory activity on the development of atherosclerosis. In isolated macrophages, we observed a small but nonsignificant effect of nicotinic acid on the expression of the cholesterol transporter ABCA1. However, nicotinic acid strongly induced expression of ABCG1 in isolated macrophages as well as in atherosclerotic vessels, an effect not seen in the absence of GPR109A (Figure 5, A and B). The upregulation of ABCG1 by nicotinic acid was accompanied by a significant increase in cholesterol efflux from WT macrophages to HDL3, whereas nicotinic acid had no effect on cholesterol efflux in macrophages from \( \text{Gpr109a}^{-/-} \) mice (Figure 5C).

To determine whether nicotinic acid is able to affect the expression of inflammatory markers in macrophages, we treated cells with IFN-\( \gamma \), resulting in a several-fold increase in monocyte chemotactic protein-1 (MCP-1) expression. Nicotinic acid strongly inhibited this effect in macrophages from WT but not from GPR109A-deficient mice (Figure 6A). Immunostaining of atherosclerotic plaques from untreated and nicotinic acid–treated mice showed that the relative fluorescence intensity of MCP-1 in MOMA-2–positive plaque areas was strongly reduced by nicotinic acid (Figure 6B), indicating that nicotinic acid reduces MCP-1 expression under in vivo conditions also. We then costained plaque macrophages in untreated and nicotinic acid–treated mice with anti-CD68 antibodies and antibodies recognizing arginase-1 and arginase-2 to determine whether nicotinic acid treatment has an effect on the differentiation state of plaque macrophages (49). While nicotinic acid had no effect on the expression of arginase-1, a marker for M2-like differentiation, nicotinic acid strongly reduced the relative fluorescence intensity of arginase-2 versus CD68 levels in a GPR109A-dependent manner (Figure 6C), indicating that nicotinic acid induces reduced M1-like differentiation via GPR109A.

To analyze potential effects of nicotinic acid on the MCP-1–dependent chemotaxis of macrophages in vivo, we determined macrophage recruitment into the peritoneal cavity in response to MCP-1 (Figure 6D). MCP-1 treatment resulted in the accumulation of macrophages both in WT and GPR109A-deficient mice, and administration of nicotinic acid blocked this effect in WT mice. However, in GPR109A-deficient mice, nicotinic acid was without effect. To determine whether the recruitment, migration, and homing of macrophages into atherosclerotic plaque was also affected by nicotinic acid, we labeled WT and \( \text{Gpr109a}^{mRFP} \) macrophages from untreated and nicotinic acid–treated mice with quantum dot nanocrystals exhibiting different fluorescence emission maxima. 2 days after adoptive transfer into atherosclerotic \( \text{Ldlr}^{-/-} \) mice, comparable numbers of untreated WT and \( \text{Gpr109a}^{mRFP} \) macrophages were detected in plaques of \( \text{Ldlr}^{-/-} \) mice (Figure 6E). Nicotinic acid reduced the recruitment of WT but not of GPR109A-deficient cells into atherosclerotic lesions by 75% (Figure 6E). Consistent with reduced recruitment of macrophages into atherosclerotic lesions under nicotinic acid treatment, we found less macrophage infiltration, as determined by quantification of CD68-positive cells (Figure 6F).

**Figure 4** Expression of GPR109A in atherosclerotic lesions. \( \text{Ldlr}^{-/-} \) mice and \( \text{Ldlr}^{-/-}; \text{Gpr109a}^{mRFP} \) mice carrying in addition a BAC transgene expressing mRFP under the control of the Gpr109a promoter (Gpr109a\(^{mRFP}\)) as well as WT mice carrying only the Gpr109a reporter transgene (Ldlr\(^{-/-}; \text{Gpr109a}^{mRFP}\)) received a high-fat diet for 16 weeks. Thereafter, animals were sacrificed, and whole-mount preparations of the aortae were photographed by normal light microscopy (A, upper panel) as well as by fluorescence microscopy to visualize mRFP expression as an indicator of Gpr109a promoter activity (A, lower panels). (B and C) Photomicrographs of \( \text{Ldlr}^{-/-}; \text{Gpr109a}^{mRFP} \) mouse aortic root cryosections showing atherosclerotic plaques. Immunofluorescence labeling was performed with antibodies recognizing macrophages (anti-Mφ, MOMA-2), and mRFP fluorescence was detected in parallel to visualize GPR109A expression. The analysis of atheroma from 3 different mice showed similar results. Margins of aortae (A) and atheroma (B and C) are marked with broken white lines. Scale bars: 37 \( \mu \)m (B); 18.5 \( \mu \)m (C). Insets in B and C show magnifications (3-fold) of the indicated areas in the overlays.
The inhibition of atherosclerosis progression by nicotinic acid in the mouse model used in the study was not accompanied by any change in HDL cholesterol or total cholesterol. There was a small decrease in triglyceride plasma levels 2 weeks after the beginning of nicotinic acid treatment, which was not seen any more after 10 weeks of treatment. It is unlikely that the transient effect of nicotinic acid on triglyceride levels strongly contributed to the antiatherosclerotic effect, since the inhibition of atherosclerosis strongly depended on the presence of the nicotinic acid receptor on bone marrow–derived cells. In addition, a small decrease in triglyceride levels after 2 weeks of nicotinic acid treatment was also observed in mice lacking the nicotinic acid receptor, although these animals did not show a reduced progression of atherosclerosis in response to nicotinic acid treatment. We therefore conclude that the beneficial effects of nicotinic acid are not only mediated through alterations in plasma lipid levels but also involve direct effects on immune cells.

GPR109A has been described as expressed in various differentiated bone marrow–derived cells including macrophages, Langerhans cells, and neutrophils, but not lymphocytes (35, 36, 38). Since macrophages within atherosclerotic lesions express GPR109A and since GPR109A on bone marrow–derived cells is required for the antiatherosclerotic effect of nicotinic acid, nicotinic acid may directly affect the function of plaque macrophages. Nicotinic acid has been shown to increase the transcriptional activity of PPARγ and to induce expression of the scavenger receptor CD36 and of the cholesterol transporter ABCA1 in monocyte/macrophage cell lines (44, 45). While we did not observe a significantly increased expression of CD36, PPARγ, or ABCA1 in nicotinic acid–treated isolated murine macrophages, nicotinic acid increased the expression of the ABCG1 transporter in macrophages from WT but not from GPR109A-deficient animals (Figure 5 and data not shown). Interestingly, an isolated upregulation of ABCG1 was recently also reported in macrophages induced by the chemokine CXCL4 (59). Together with our data indicating a reduced arginase-2 expression in nicotinic acid–treated macrophages in vivo, these data show that nicotinic acid can change the differentiation state of macrophages both in vitro and in vivo. Both ABCA1 and ABCG1 mediate the transport of cellular cholesterol to ApoAI-containing HDL particles for the reverse cholesterol transport pathway (60). In isolated macrophages, we observed that nicotinic acid pretreatment enhanced
Figure 6
Effect of nicotinic acid on gene expression and macrophage recruitment in WT and Gpr109a–/– mice. (A) Peritoneal macrophages from WT or GPR109A-deficient mice (Gpr109a–/–) were treated for 4 hours without or with 100 μM nicotinic acid and 20 μg/μl IFN-γ as indicated, and expression of MCP-1 mRNA was determined (mean values ± SEM [n = 6]). (B and C) MCP-1 expression in plaque macrophages (B) and expression of arginase-1 and arginase-2 in the CD68-positive area (C) in untreated and nicotinic acid–treated atherosclerotic mice (mean ± SEM; n = 5 mice). (D) MCP-1–induced recruitment of peritoneal macrophages. Shown are mean values ± SEM (n = 6). (E) Homing of WT and GPR109A-deficient (Gpr109a–/–) macrophages into atherosclerotic lesions. Shown is the number of macrophages homing into lesions of the aortic root 2 days after intravenous injection in the absence or presence of nicotinic acid. (F) CD68-positive macrophages in lesions of aortic roots from untreated and nicotinic acid–treated Ldlr–/–;Gpr109a+/+ or Ldlr–/–;Gpr109a–/– mice. Shown are data from at least 5 different animals (mean values ± SEM). (G) VCAM-1, ICAM-1, and P-selectin mRNA levels in aortae of Ldlr–/– mice that had been transplanted with Gpr109a+/+ or Gpr109a–/– bone marrow. Animals were kept on a high-fat diet for 16 weeks and were treated without or with nicotinic acid (mean values ± SEM [n ≥ 6]). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
Efflux of cholesterol to HDL particles and that this effect depended on the presence of GPR109A. Despite the differences between our data on primary macrophages and those reported in macrophage cell lines, increasing evidence indicates that nicotinic acid enhances cholesterol transport out of macrophages.

In isolated macrophages, we observed that nicotinic acid inhibits the upregulation of MCP-1 expression in response to IFN-γ, an effect that was absent in macrophages from GPR109A-deficient mice. Similarly, we also observed a decreased expression of MCP-1 in plaque macrophages after nicotinic acid treatment. Inhibition of the expression of inflammatory mediators by nicotinic acid was recently also shown in adipocytes in which nicotinic acid suppressed expression of various chemokines including MCP-1 while increasing the expression of adiponectin (61, 62). Since chemokines and nicotinic acid regulate cellular functions through receptors coupled to G i-type G-proteins (63, 64) and thereby initiate identical cellular signaling processes, it is conceivable that the activation of GPR109A by nicotinic acid given systemically can alter the effects of chemokines acting on the same cell. Consistent with that, we found in a model for MCP-1-induced chemotaxis in vivo that nicotinic acid inhibited the effect of MCP-1. This inhibitory effect was not seen in GPR109A-deficient mice. Thus, activation of GPR109A appears to interfere with chemokine effects. In adoptive transfer experiments with WT and GPR109A-deficient macrophages, we saw that nicotinic acid inhibited the homing of WT but not of receptor-deficient cells to atherosclerotic lesions of Ldlr–/– mice. Since MCP-1 and other chemokines are critical mediators of immune cell recruitment into the atherosclerotic vessel wall, a disturbance of chemokine signaling by nicotinic acid may contribute to the antiatherosclerotic effect of nicotinic acid. In this respect, it is interesting that activation of the cannabinoid receptor CB2, which is also coupled to G i-type G-proteins and which is expressed on immune cells including macrophages, reduces progression of atherosclerosis and inhibits macrophage chemotaxis by interfering with intracellular signaling processes induced through chemokine receptors (65–67).

Consistent with recent in vitro and in vivo data (32–34), we saw a reduced expression of adhesion molecules in atherosclerotic vessels of nicotinic acid–treated Ldlr–/– mice. The observed reduction in VCAM-1 and P-selectin mRNA levels were, however, not seen in Ldlr–/– mice transplanted with Gpr109a–/– bone marrow. In the case of VCAM-1 expression, we cannot rule out that part of the reduced expression in response to nicotinic acid is due to direct effects of nicotinic acid on plaque macrophages that also express VCAM-1. These data strongly indicate that the reduced expression was not due to direct effects of nicotinic acid on endothelial cells but involved activation of GPR109A on immune cells.

We also cannot exclude that other bone marrow–derived cells such as neutrophils, which have been shown to play a role in atherosclerosis progression (68), are involved in the antiatherosclerotic effects of nicotinic acid. Neutrophils express GPR109A, and nicotinic acid exerts a proapoptotic effect in neutrophils under in vitro conditions (40).

Our findings strongly indicate that nicotinic acid has direct effects on bone marrow–derived cells that are mediated by GPR109A and that these effects in addition to its antidyslipidemic effects are important for the antiatherosclerotic properties of this drug. Given the widespread expression of the nicotinic acid receptor GPR109A on immune cells, the antiinflammatory potential of nicotinic acid and other GPR109A agonists needs to be further explored. While new strategies to reduce inflammation and to increase reverse cholesterol transport by regulating the function of immune cells have been proposed as a new approach to treating atherosclerosis (69–71), our data show that one of the established antiatherosclerotic drugs in fact exerts its beneficial effect at least in part through mechanisms involving direct effects on leukocytes. These data strongly support a role for antiatherosclerotic mechanisms beyond lipid-altering effects and reveal what we believe is a new mechanism of action for one of the oldest drugs used to prevent and treat atherosclerosis.

Methods

Reagents and antibodies. A high-fat diet containing 21% butter fat and 1.5% cholesterol was from ssniff. Nicotinic acid, oil red O, Brewer’s thyoglycolate, and recombinant mouse GM-CSF were from Sigma-Aldrich. Recombinant rat IFN-γ was purchased at PeproTech, and recombinant mouse JE (MCP-1) was from Invitrogen. Macrophages were detected using rabbit anti-mouse macrophage antibodies (Accurate Chemical & Scientific Corp.), rat anti-mouse MOMA-2 or anti-CD68 antibodies (Serotec), and goat anti-rabbit IgG or goat anti-rat IgG (Cy3) secondary antibodies (Alexa Fluor 488) from Invitrogen. Rabbit anti-mouse MCP-1 and rabbit anti-mouse arginase 2 antibodies were from abcam. Anti-arginase 1 antibody (BD Biosciences) was visualized with goat TRITC-labeled anti-mouse IgG (Invitrogen).

Genetic mouse models. Ldlr–/– mice were obtained from the Jackson Laboratory, and Gpr109a–/– mice have been described previously (20). The generation of a Gpr109a expression reporter mouse line (Gpr109aGFp) was recently described (48). All experiments were performed with male mice, and the animals were kept on a C57BL/6 background. All procedures of animal care and use in this study were approved by the local authorities (Regierungspräsidium Darmstadt and Karlsruhe).

Determination of plasma lipid levels. Total cholesterol and triglyceride levels were determined in the plasma of nonfasted mice kept on a high-fat diet for the indicated time periods with assay kits from Sigma-Aldrich, and free fatty acid concentration was measured using an enzyme-based colorimetric assay kit from Randox according to the manufacturers’ instructions. The distribution of cholesterol among different lipoprotein particles was analyzed by size-exclusion fast protein liquid chromatography (FPLC) followed by the determination of the cholesterol content in collected fractions. Serum samples were pooled and loaded (200 μl) onto a Superose 6HR 10/30 column (Amersham), and lipoproteins were separated at a flow rate of 0.2 ml/min of PBS at pH 7.4. Fractions of 0.5 ml were collected, and the cholesterol concentration was determined.

Bone marrow transplantation. Bone marrow was obtained aseptically from femora and tibiae of Ldlr–/–, Ldlr–/–;Gpr109a–/–, or Ldlr–/–;Gpr109aGFp–/– mice. Cells (5 × 106/mouse) were resuspended in sterile PBS and transplanted by intravenous infusion into lethally irradiated (10 Gy) Ldlr–/– recipients 1 day after irradiation at the age of 8 weeks.

Induction and quantification of atherosclerosis. To induce atherosclerosis in Ldlr–/– mice, animals were fed with a high-fat diet ad libitum for the indicated periods. Anesthetized animals were perfused with PBS via the left ventricle, followed by 4% paraformaldehyde, 5% sucrose, and 20 mM EDTA in PBS, pH 7.4. After dissection and removal of adherent fat tissue, the aorta was immersed in the above buffer overnight. After removal of the adventitia, the aorta was opened longitudinally, pinned flat onto a dissecting wax, and stained with oil red O. Afterwards, aortas were mounted with glycerol gelatine onto a slide and photographed. The total aortic area and stained aortic lesion area were manually outlined in a blinded fashion and analyzed using Adobe Photoshop CS3, and the lesion size as a percentage of the total aortic area was determined. To evaluate atherosclerosis in the outflow tract and valve area of the heart, the top half of the heart was removed and immersed in the above buffer overnight followed by incubation in 30% sucrose. The hearts were embedded in OCT and stored at

The Journal of Clinical Investigation
-80 °C until sectioning. Serial 10-µm sections were cut through the part of the aortic root, where all 3 valve leaflets were present (72). For each mouse, sections separated by 50 µm were examined systematically. Each section was stained with oil red O and mounted in glycerol gelatine. Sections were photographed and analyzed blinded using Adobe Photoshop CS3.

**Fluorescence imaging of Gpr109a and immunostained macrophages.** Cryosections were fixed by incubation in −20 °C acetone for 2 minutes and rehydration in PBS. Endogenous peroxidase was quenched with 0.3% hydrogen peroxide. Nonspecific staining was blocked by incubation with 5% normal goat serum for 1 hour at room temperature. Sections were incubated overnight at 4 °C with the following primary antibodies, either alone or in combination as indicated: polyclonal rabbit anti-mouse macrophage antigen serum (1:100), rat anti-mouse MOMA-2 antibody (1:100), rat anti-mouse CD68 antibody (1:200), mouse anti-mouse arginase 1 antibody (1:100), rabbit anti-mouse arginase 2 antibody, and rabbit anti-mouse MCP-1 antibody (1:100). Primary antibodies were visualized with fluorescein-labeled Alexa Fluor 488–labeled goat anti-rabbit IgG, Cy3-labeled goat anti-rat IgG, or TRITC-labeled goat anti-mouse IgG secondary antibodies (1:200). Stained sections were mounted in Aqua-Poly/Mount medium and analyzed by confocal microscopy (Leica TCS SP2).

**Recruitment of peritoneal macrophages.** WT and Gpr109a+/− mice were injected intraperitoneally with 1 ml of autologous 4% Brewer’s thiglycollate medium. After 4 days, mice were injected intraperitoneally with 0.9% NaCl or nicotinic acid (30 mg/kg) 1 hour prior to a second injection with 0.9% NaCl and murine MCP-1 (20 µg/kg) or murine arginase-1, and murine MCP-1, as indicated. After 3 hours, peritoneal cells were collected by lavage with 15 ml of PBS containing 5 mM EDTA and were counted.

**Macrophage boning assay.** Analysis of macrophages recruited into atherosclerotic lesions was performed with modifications as described (73, 74). Peritoneal macrophages were obtained as described above. 14 days prior to the isolation, donor mice were treated without or with 0.3% nicotinic acid. Mice were then treated with vehicle or nicotinic acid (100 µM) 1 hour prior to incucation with IFN-γ in the presence or absence of nicotinic acid. Three hours later, cells were lysed, and total RNA was harvested using the RNeasy Micro Kit (Qiagen). RNA from aortic arches or whole-mount aortae was isolated with RNeasy FFPE Kit (Qiagen). Quantitative PCR was conducted in reactions containing cDNA from 600 ng total RNA (peritoneal macrophages and whole mount aortae) or 250 ng total RNA (aortic arches) with SYBR green indicator and SYBR green indicator. Data were analyzed with REST-384 software (77). Results are expressed as expression ratios of cross threshold (Ct) values for target genes normalized to the Ct of β-actin considering individual PCR efficiencies. The oligonucleotide primer sequences were as follows: MCP-1 forward: 5′-GCAACACTCT-CACCTGAAGGC-3′, reverse: 5′-GCCTGTGAAATGAGTACAGCAGC-3′ (78); ABCA1 forward: 5′-GGACGTGGGAAGTCAACAC-3′, reverse: 5′-ACATGCTCTTCCTCCCCGTACG-3′; ABCG1 forward: 5′-GCCTGTGGCTTGGTTTGCTGTT-3′, reverse: 5′-TGCACTTCACTCTGATCTTCAAT-3′ (79); VCAM-1 forward: 5′-CCCCAAGATTGCTCAGAGTCA-3′, reverse: 5′-ACTTGAGGCTACCCGCCTGTT-3′; ICAM-1 forward: 5′-ATCTCAGGCCGAAGGG-3′, reverse: 5′-CGAAATGCGGCCGTCCTCC-3′; P-selectin forward: 5′-CCATGCGCCCTGCCCTCACG-3′, reverse: 5′-GGCTACTGGTCTCCATTGTC-3′; and β-actin forward: 5′-TGACTGATACATCCGTAAAGACG-3′, reverse: 5′-TGCTAGAGCCAGACAGTAA-3′ (80).

**Statistics.** All results are expressed as the mean ± SD, except where noted. Mean values between 2 groups were analyzed with 2-tailed t test; data sets containing multiple groups were analyzed by ANOVA. P < 0.05 was considered significant.

**Acknowledgments**

We thank Manuela Ritzal, Karin Meyer, the Nikon Imaging Center at the University of Heidelberg, and the lipidomic facilities (MetaToul platform) of the Bio-Medical Research Federative Institute of Toulouse (IFR150) for expert technical assistance and Rose LeFaucheur and Svea Hümer for excellent secretarial help. S. Offermanns was supported by the German Research Foundation.

Received for publication November 3, 2009, and accepted in revised form December 15, 2010.

Address correspondence to: Stefan Offermanns, Department of Pharmacology, Max-Planck-Institute for Heart and Lung Research, Ludwigstr. 43, 61231 Bad Nauheim, Germany. Phone: 49.0.6032.705.1201; Fax: 49.0.6032.705.1204; E-mail: stefan. offermanns@mpi-bn.mpg.de.

Andrea Gille’s present address is: CSL Ltd., Clinical and Translational Science Department, 45 Poplar Road, Parkville, Victoria 3052, Australia.

Jukka Kero’s present address is: Department of Physiology, Institute of Biomedicine, Kuinnamyllynkatu 10, 20520 Turku, Finland.


77. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res*. 2002;30(9):e36.

